Xiangyu He, MD
PhD CandidateDepartment of Cardiac Surgery
Member of the CARE Team
Keywords
Artificial Organs; Heart Failure; Cardiovascular Diseases; Assisted Circulation; Surgery; Blood
Research interests
Left ventricular assist device (LVAD) is a well-established therapy for end-staged heart failure patients. However, the severe hemocompatibility related adverse events (HRAEs) such as bleeding of HM3 are still observed in clinic. My main research focus is to investigate the impact of hemodynamics on hemocompatibility regarding hemolysis, platelet activation and vWF degradation of the HeartMate 3 (HM3) under realistic operation conditions.
Techniques, methods & infrastructure
To study the link between hemodynamics and hemocompatibility, I will define the boundary conditions of HM3 in left atrial decompression for heart failure with preserved ejection fraction (HFpEF) and perform virtual fitting of HM3 for this population. In addition, I will carry out in-vitro blood experiment under realistic operation conditions in a hybrid mock loop to study the hemolysis, platelet activation and vWF degradation with human blood. Meanwhile, I will compare the influence of different anticoagulants on the hemocompatibility of HM3.
Research group(s)
- CARE - Cardiovascular Research and Engineering
Selected publications
- He, X. et al. ‘Left Atrial Decompression the HeartMate3 in Heart Failure With Preserved Ejection Fraction: Virtual Fitting and Hemodynamic Analysis’, ASAIO J. 2024 Feb 1;70(2):107-115. Available at: http://dx.doi.org/10.1097/MAT.0000000000002074